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Historical Perspective
Epidemiological studies of viral hepatitis in the late
1930s and early 1940s defined two clinical syndromes.
The first, infectious hepatitis, described epidemic jaun-
dice occurring in crowded living areas and spread by the
fecal-oral route. The incubation period was short, three
to six weeks, and the prodrome was abrupt. The second
form, serum hepatitis, described sporadic cases occur-
ring predominately after blood transfusion and spread by
the parenteral route. The incubation period was longer
than that for infectious hepatitis, up to 6 months, and the
onset of clinical illness was frequently insidious or inap-
parent. Chronic liver disease was seen only with serum
hepatitis, while fulminant liver disease was seen in both
varieties, although more commonly with serum
hepatitis. It is clear now that infectious hepatitis and
serum hepatitis describe hepatitis A virus and hepatitis B
virus infection, respectively. Viral hepatitis not caused
by hepatitis A or B virus or known viruses causing hepa-
tic damage (eg, Toxoplasma, CMV, EB virus, herpes,
adenovirus), has recently been described and designated
as nonA, nonB hepatitis. Recent developments clarifying
the populations at risk for infection, the potential
sources for infection, the clinical stages of viral hepatitis,
and the role for immunoprophylaxis (vaccine and
gamma globulin), in each of these three major viral
hepatitides will be described.
Epidemiology
Hepatitis A
The most common mode of transmission of type A
virus (HAV) is from person to person by the fecal-oral
route.''^'^ HAV is maintained in human populations
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through serial propagation and not by a carrier state.
This accounts for the explosive outbreaks which have
occurred in susceptible populations. One major excep-
tion to direct human to human transmission is shellfish-
associated hepatitis, which has contributed significantly
to the endemic occurrence of type A hepatitis in some
areas. Oysters, clams, and other mollusks filter large
volumes of infected water daily, trapping and thereby
concentrating the virus.^
HAV is world-wide in distribution with typical fea-
tures including (a) a low mortality rate, (b) familial
aggregation due to a high attack rate among household
members, (c) a higher attack rate among young children,
(d) higher prevalence in lower socioeconomic classes,
(e),higher attack rates in rural compared to urban popu-
lations, and (f) a cyclic tendency with seasonal varia-
tion.'-^'^ These factors suggest that HAV transmission is
largely dependent upon poor personal hygiene and sani-
tation, which occurs more commonly under crowded
living conditions such as institutions for the mentally
retarded, army camps, and prisons. Individuals with
Down's syndrome (associated with immunodeficiency)
do not have a higher HAV attack rate than other in-
stitutionalized infants. However, other unrecognized
factors must come into play to explain varying HAV pre-
valence (as measured by the prevalence of antibodies to
HAV (anti-HAV) in populations with similar standards of
living (12% —Philadelphia, 41% —New York City,
60%—Warsaw, 95%—Tel Aviv, 87% —Belgium).^
Numerous studies have failed to incriminate HAV in a
significant number of cases of post-transfusion or hemo-
dialysis-associated hepatitis although blood obtained
from a patient in the early prodrome can transmit
hepatitis. Vertical transmission from mother to fetus,
common in hepatitis B infection, is rare for hepatitis A.
Although in the past homosexuality had not been con-
sidered a risk factor for HAV transmission, a recent study
suggests the opposite. Corey and Holmes* found the
prevalence of anti-HAV to be 30% in homosexual men
as compared to 12% in heterosexual men. The annual
seroconversion to anti-HAV positivity was 22% in
homosexual men, whereas no heterosexual men de-
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veloped this marker. Frequent oral-anal contact between
homosexual men was proposed by the authors as the
basis for this increased risk.
There has been a downward trend in hepatitis A cases
in the U.S. The case rate for 1977 (14.4 cases/100,000)
was one half that observed in 1971 (28.9 cases/
100,000).^ Possibly this decreased incidence is even
greater because of improvements in diagnosis. This de-
crease is consistent with a post-epidemic phase of HAV
(similar to measles and polio) in which the disease rate
falls to low levels because of improvements in hygiene,
sanitation, housing, and a decline in the susceptible
population.
Hepatitis B
Hepatitis B virus has been well studied because ofthe
availability of sensitive serologic markers. '̂̂  The major
mechanisms of HBV transmission are (a) close personal
contact involving salivary exchange (b) sexual contact
and (c) vertical transmission from mother to offspring.^-*
In the U.S.A., however, HBV is still most commonly
spread through the parenteral route, particularly in pa-
tients who abuse intravenous drugs. Blood transfusions
are now a minor source for HBV since blood is screened
for hepatitis B surface antigen (HBsAg), and commercial
blood donation is declining in this country. HBsAg is
detectable in numerous body secretions including
saliva, urine, breast milk, semen, vaginal secretions and
menstrual blood, although infectivity has never been
shown for any of these secretions. Animals can harbor
the virus (mosquitoes, bed bugs) but spread from these
sources appears rare.' Continuous or multiple exposures
to HBV may explain the high risk for infection in dialysis
patients, sexual contacts, homosexuals, health person-
nel, and institutionalized patients.'-*-'"-"
Immune deficiency is important in determining both
the clinical expression of HBV and its tendency to
chronicity. Patients with chronic renal failure rarely de-
velop icteric hepatitis and frequently develop a chronic
carrier state (10-15%). In contrast, staff members in
dialysis centers, if infected, develop icteric hepatitis with
a lower incidence of a chronic carrier state (1.5-2%). A
similar effect can be seen in institutions for the mentally
retarded. Children with Down's syndrome, in whom cell
mediated immune deficiency has been documented,
have a carrier rate of 30-40% while similarly exposed
immunocompetent inmates have only a 5-15% carrier
Blood contact and heritage have a bearing on the pre-
valence of HBsAg in a population. Approximately 1 -4%
ofthe U.S. population is positive for HBsAg. This carrier
state may be ten times higher in repeat blood donors as
compared to those who donate blood for the first time
(1.9% vs 0.2%). Ethnic subpopulations show significant
differences in HBsAg carriage (eg, 2.3% in Chinese-
Americans, 0.6% in blacks, and 0.07% in Jews).̂  The
major factors favoring a higher rate of HBsAg positivity
in mixed populations include lower socioeconomic
class, male sex, and most importantly, the country of
origin.^'^-^-'^
The high incidence of HBV infection associated with
dialysis units and medical personnel deserves special
comment. The prevalence of hepatitis B surface antigen
(HBsAg) and/or antibody to the HBsAg (anti-HBs) in
most studies ranges between 50-70% for dialysis pa-
tients and 30-40% for dialysis staff.̂ -'̂  The higher preva-
lence of HBsAg in patients may be related to their inabil-
ity to effectively clear the virus during the initial infec-
tion and not necessarily to a greater degree of exposure.
In the general population, both HBsAg and anti-HBs are
more common among non-white patients. In contrast,
within dialysis units, non-white patients have a higher
prevalence of anti-HBs but a lower prevalence of
HBsAg.*-'^ This may be a consequence of the higher
level of prior exposure in non-whites, protecting them
against reinfection and the development of antigenemia
after renal dialysis begins. Since approximately 50-80%
of anti-HBs positive patients have never received trans-
fusions, other body fluids may play an important part in
the transmission of disease.
Dentists are exposed to HBV that is present either con-
tinuously or intermittently in the saliva of a large propor-
tion of HBsAg carriers. In addition, they often work in a
field which is contaminated with blood. Studies in the
United States and Canada have shown that the fre-
quency of HBsAg (0.3-1.3%) is not higher in dentists
than in the blood donor population, although the fre-
quency of anti-HBs (12-16% compared to 3-8.7% in
controls) is clearly increased.'^-'"'-'^ Therefore, there is
evidence for an increased exposure of dentists to HBV
and measures to decrease exposure such as wearing
gloves merit investigation.'®
Physicians are also at higher risk, with a prevalence of
HBsAg more than five times that of a comparable group
of volunteer blood donors.'^ Oriental physicians, those
practicing in an urban setting, and those in the early
years of clinical practice are at highest risk. Surgeons
and pathologists, with the greatest exposure to blood
and tissue fluids, have a ten times greater incidence of
anti-HBs than other physicians. Two-thirds of the anti-
HBs positive physicians denied an episode of clinical
hepatitis.'"-'* Health personnel, as a high-risk group,
may benefit from the development of an HBV vaccine.
As opposed to HAV, there has been a long-term trend
for an increased incidence of HBV infection. The case
rate for 1977 (7.8/100,000) was almost twice that for
1970 (4.8/100,000),^ but much of this may reflect in-
creased sophistication in HBV detection.
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NonA, NonB Hepatitis
Accurate diagnosis of HAV and HBV infection has
identified a large number of patients with acute
hepatitis who are negative for A and B markers. These
cases are now designated as nonA, nonB hepatitis.
Whether or not these cases are due to one or more viral
agents is unknown. Recent work has identified DNA
containing virions obtained from marmosets infected
with blood known to transmit nonA, nonB hepatitis.'*-'"
Since markers for nonA, nonB hepatitis are lacking,
few definite statements can be made about the epidemi-
ology of this disease. NonA, nonB hepatitis is similar to
HBV in that intravenous drug addicts are at high risk and
that progression to chronic hepatitis may occur. Now
that blood banks routinely screen for HBsAg, nonA,
nonB virus(es) are responsible for approximately 90% of
transfusion-associated hepatitis.
Clinical Spectrum
Knowledge of the natural history of viral hepatitis has
expanded with the development of assays for viral anti-
gens, antibodies, and biochemical markers of hepatic
injury (transaminases). Hepatitis A virus, hepatitis B
virus, and the nonA, nonB virus(es) represent the major
viral agents causing hepatitis. The natural history of
hepatitis A and hepatitis B infections can be divided into
seven clinical stages: incubation period, prodrome,
symptomatic phase, resolution phase, anicteric hepatitis,
the chronic carrier state, and chronic hepatitis.'" Al-
though nonA, nonB hepatitis can also be subdivided in a
similar manner, studies are preliminary since im-
munologic viral markers are not currently available.'"-^"
Incubation Period
The incubation period for viral hepatitis can be de-
fined in several ways and has undergone revision in the
last 50 years.̂ ^ When defined as the interval between
exposure and the onset of jaundice, the incubation pe-
riod averaged 40 days for hepatitis A and 90 days for
hepatitis B.'"-^' This period was used for a long time to
discriminate between these viral infections. Studies car-
ried out in the mid-1960s, using transaminases as the
marker for infection, showed a mean incubation period
of 40 days for hepatitis B. Further modifications in the
early 1970s, using immunoprecipitin tests for hepatitis B
surface antigen (HBsAg), showed that B infection could
be detected as early as 21 days after exposure with a
mean of 29 days. '̂ More sensitive radioimmunoassays
for HBsAg and immune assays for hepatitis A virus
(HAV) in stool have clearly shown that viremia and viral
excretion can occur in the first week after exposure. '̂-^^
The time from exposure to the onset of biochemical ab-
normalities or jaundice for nonA, nonB hepatitis is simi-
lar to that for hepatitis B infection. The implication for
prophylaxis of viral hepatitis is clear. Since gamma
globulin is most effective if given before or at the time of
viremia, the injection must be given as early as possible
after exposure (<1 week). Thus, early detection of viral
hepatitis is mandatory and recognition of the popula-
tions at risk for contracting infection is required for effec-
tive prevention (Table 1).
Detection of viral hepatitis during the incubation pe-
riod is difficult. Most patients are asymptomatic during
this period. Liver chemistries including bilirubin and
transaminases (SGOT, SGPT) are normal. A serum
sickness-like syndrome has been described for hepatitis
B infection during the incubation period.^^ Multi-organ
involvement including arthralgias, arthritis, and glomer-
ulonephritis caused by deposition of immune complexes
(HBsAg-anti-HBs) and complement can precede
symptomatic hepatitis by as much as six weeks.
The skin changes during hepatitis B viral infection can
vary from a simple viral exanthem to diffuse vas-
culitis.^^-^" The skin lesions may occur in the presence or
absence of other manifestations of serum sickness and
usually begin as an erythematous macular or
maculopapular eruption predominately on the trunk and
limbs, which can progress to a hemorrhagie rash.'^-^''
These eruptions may last for weeks but usually decrease
or disappear with the onset of jaundice. Examination of
the skin for HBsAg, anti-HBs, or complement will fre-
quently be negative during the erythematous or
maculopapular stage but is positive in the majority of
cases if purpura develops. Urticaria, subcutaneous non-
tender nodules which can ulcerate and a eireinate rash
resembling rheumatic fever have also been reported but
their relationship to immune complex deposition is un-
known. Infantile papular acrodermatitis, which occurs in
young children, particularly toddlers, and consists of
rapidly spreading nonitching erythematous papules on
the face and limbs, has been causally related to HBV
infection. Spontaneous regression (usually in one month)
coincides with disappearance of surface antigen.'"
Recognizing the etiology of this syndrome requires
clinical suspicion and sensitive assays for viral markers.
HBsAg can usually be detected although tests may be
negative secondary to complexing with anti-HBs. Im-
munofluorescent staining of affected tissues or examina-
tion of the immune complexes will usually reveal the
etiology.^^'" To date, only hepatitis B has been as-
sociated with immune complex disease. Hepatitis A and
nonA, nonB hepatitis cannot be detected in the incuba-
tion period and exposure to the viruses must be
documented for effective
Prodrome
Early symptoms of hepatitis are nonspecific and are
similar to most enteroviral infections.'"-^" Nausea, vomit-
ing, diarrhea, low grade fever, respiratory complaints.
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headache, and malaise are common. These symptoms
may herald the onset of overt jaundice but may be the
only manifestations of anicteric hepatitis. Physical
examination may reveal lymphadenopathy and
splenomegaly but is usually unremarkable except for the
tender right upper quadrant with or without mild
hepatomegaly. Serum bilirubin is usually normal al-
though bilirubin in the urine (eg, dark urine) may be the
first sign of hepatitis. Transaminases are elevated and
viral markers (HBsAg, HAV in stools) are present in the
majority of cases. Signs of viral replication in the liver
(hepatitis B or hepatitis A virus in the blood, or antibody
to B core antigen [anti-HBc]) are detectable at the time
of rising transaminases.'̂ •^"• '̂ High risk groups such as
recipients of blood products, renal dialysis patients, in-
travenous drug users, hospital personnel or immunosup-
pressed patients should be screened for hepatitis by
measuring transaminases if symptoms of a viral syn-
drome occur. Prolonged viral illness may be the only
sign of anicteric hepatitis and measurement of trans-
aminases is appropriate in this setting. Hepatitis A virus
excretion is highest during this period. Thus, early rec-
ognition is important to prevent transmission of
hepatitis.'^ Hepatitis B viremia and fecal excretion are
highest during the late prodromal-early symptomatic
phases although viremia and low grade fecal excretion
continue throughout the course and disappear when the
patient becomes HBsAg negative.'^•^'''^'
Symptomatic Phase
Jaundice is the hallmark of this phase of illness. Mul-
tiorgan involvement can occur during this period.
Myopathy, pancreatitis, cardiomyopathy, cranial and
peripheral nervous system disease, as well as aplastic
anemia and agranulocytosis have been reported rarely
and are a major cause of mortality if they develop. Most
patients, however, have a self-limited disease and do not
require hospitalization. Those patients in whom
adequate rest, nutrition, or hydration cannot be main-
tained or those with evidence of more serious infection
(increased prothrombin time or rapidly decreasing al-
bumin) may require hospitalization.^^ Patients who have
poor hygiene or live in crowded domestic situations (in-
stitutions, large families) require isolation to prevent
intra-household spread." Neither serum bilirubin nor
the level of transaminases are helpful in predicting the
outcome or the need for hospital care.'^ However, in-
creasing bilirubin after two weeks of jaundice, particu-
larly if associated with falling transaminases and a
shrinking liver, suggests a poor prognosis. Even under
these circumstances, however, hospitalization has not
been shown to be of benefit unless complications (such
as bleeding) occur.
The treatment and handling of patients at home or in
the hospital is similar and dependent on meticulous









































hygiene."-^* Treatment is supportive since no specific
therapy is available, and most cases are self limited. Cor-
ticosteroids have been shown to be ineffective or
deleterious.'** Proscription against alcohol or other
hepatotoxins seems reasonable although direct evidence
for a benefit is lacking.'" Activity should be restricted
during the period of jaundice although in the young and
previously healthy patient this may be unnecessary.'̂
The diet need not be changed from the ordinary unless
gastrointestinal distress increases. Medications, particu-
larly sedatives, should be used with caution during this
phase since drug accumulation can be pronounced dur-
ing viral hepatitis.
Spread occurs predominately through blood or inti-
mate contact such as with sexual partners, small chil-
dren and nursing infants. Sexual relations and heavy ex-
posure to oral secretions (kissing, shared toothbrushes,
utensils, shavers), should be avoided during the acute
illness. Hand washing and other forms of personal
hygiene are usually sufficient to prevent infection.
Avoidance of blood contact, particularly with hospital
personnel and identification of infected blood samples,
will decrease in-hospital spread. Strict isolation is only
required where the above measures cannot be im-
plemented .̂ '̂̂ ''•̂ ''
Resolution Phase
The clinical course of viral hepatitis is variable.
Hepatitis A has a more benign course with more rapid
resolution than hepatitis B or nonA, nonB hepatitis but
can be fulminant with massive necrosis and death.^^ The
time from the onset of jaundice to normalization of
transaminases averages four weeks in hepatitis A but can
be three to six months in hepatitis B or nonA, nonB viral
infections.'^ Hepatitis B infection can manifest itself as
severe cholestasis, increasing bilirubin or alkaline
phosphatase, and pruritus in about 5% of cases, with
persistent elevations of bilirubin for up to one year with-
out signs of clinical hepatic deterioration (ie, decreasing
synthetic function such as decreasing albumin or in-
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creasing prothrombin time).'" Typically, resolution be-
gins with an increased sense of well being and improved
appetite. Biochemically, bilirubin peaks and begins a
gradual descent while transaminases may drop rapidly.
Viral markers such as HBsAg may still be positive, how-
ever, and the patient is potentially infectious. Clinical
relapse is rare and unpredictable. Jaundice is usually less
severe than during the initial symptomatic phase and
should be handled in a similar manner. Biochemical
relapse (rising transaminases) is more common and
needs no specific treatment unless the patient is
symptomatic. Return to work should be delayed until the
patient can ambulate without excessive fatigue, has
normal or almost normal transaminases («4 x NL), and
preferably is HBsAG negative. Although HBsAG
positivity does not mean infectivity, temporary reas-
signment of workers, who may potentially spread infec-
tion by fecal-oral or blood contact (food handlers, blood
drawers, surgical technicians) would be judicious until
they are HBsAG negative.'"-"-^* Protective antibodies
(anti-HAV, anti-HBs) appear late after clinical recovery,
averaging six to eight weeks for anti-HAV and 16 weeks
for anti-HBs. Anti-HAV, anti-HBs, and anti-HBc may
persist for life, and thus, their presence only signifies past
Anicteric Hepatitis
Anicteric disease has been well documented in 90%
of patients with hepatitis A, 80% with hepatitis B, and
60-70% of patients with nonA, nonB hepatitis. In ret-
rospect, 50% of these anicteric episodes occurred with-
out discernible symptoms. The high incidence of viral
antibodies to hepatitis A (anti-HAV in 40% of New York
City residents)^' and hepatitis B (1 % of blood donors, up
to 10% of drug addicts)'-'"-2" all indicate a high inci-
dence of anicteric hepatitis.
Chronic Carrier State
Only hepatitis B virus has a documented chronic car-
rier state.̂ '-^"-^^ NonA, nonB hepatitis may result in a
chronic carrier state but immune markers are lacking to
confirm this.̂ ^- '̂' Blood taken from patients years after
the initial infection with nonA, nonB hepatitis has been
shown to transmit hepatitis to marmosets.̂ -̂̂ ®-̂ '̂  The
chronic carrier state for HBV is defined as the persist-
ence of HBsAg for six months or longer, although this
marker can disappear up to two years after infection.
Annual estimates of HBsAg positivity have shown that
three percent of HBsAg chronic carriers lose this marker
annually.'" However, most chronic carriers of HBsAg
will remain so for life. Chronic carriers are usually not
infective nor develop chronic liver disease, particularly
if the serum transaminases are normal. Hepatitis B
e-antigen (HBeAg) may be a marker for increased infectiv-
ity but patients negative for HBeAg can still transmit
hepatitis by blood transfusion.̂ **-̂ " Personnel and patients
in high risk areas such as dialysis units or oncology wards
need frequent screening (HBsAg and transaminases) to
prevent hepatitis transmission. Personal hygiene is of
paramount importance until adequate vaccines are de-
veloped for these high risk individuals.
Chronic Hepatitis
Hepatitis A does not produce chronic hepatitis.
Hepatitis B viral infections produce chronic hepatitis in
10% of patients."*" The majority of these patients will
have mild or no fatigue, mild elevations of trans-
aminases, and liver biopsies showing localized peripor-
tal inflammatory disease. Protein electrophoresis reveals
a normal gamma globulin. This form of chronic hepatitis
is called persistent hepatitis and does not appear to pro-
gress to cirrhosis. Approximately 1-3% of patients with
HBsAg positive hepatitis will develop progressive liver
disease manifested by moderate to marked elevation of
transaminases with or without an increased bilirubin,
disabling symptoms of fatigue, and stigmata of chronic
liver disease (vascular spiders, palmar erythema,
gynecomastia).'"' Protein electrophoresis will consist-
ently show elevated gamma globulin levels (absolute
level >2.0 gms%) in symptomatic patients.'"-^" This en-
tity is called chronic active hepatitis and has a high inci-
dence of progression to cirrhosis. Liver biopsy reveals
loss of hepatocytes with significant fibrosis and necrosis
between central and portal veins called bridging necro-
sis. Liver failure, portal hypertension with hyper-
splenism, and variceal bleeding are common al-
though the clinical course and outlook appear better
than with alcoholic cirrhosis.^' Treatment with steroids is
frequently ineffective, despite high doses, in the majority
of patients with hepatitis B chronic active hepatitis."*^
Chronic hepatitis following nonA, nonB hepatitis has
a more benign course than that following hepatitis B.
Although persistently elevated transaminases have been
demonstrated for up to two years in 30% of patients after
acute nonA, nonB hepatitis,^^ the majority of these pa-
tients will have persistent hepatitis. No case of progres-
sive liver disease with bridging necrosis has been
documented. Inactive cirrhosis has been found, but the
natural history of this lesion is unknown. Recent
serologic investigations of patients with cryptogenic cir-
rhosis have shown a high incidence of previously un-
diagnosed hepatitis B infection.'" The contribution of




Immunoprophylaxis of hepatitis was initiated in the
1940s when the use of gamma globulin was shown to be
effective in populations exposed to infectious
hepatitis."* '̂** However, only in the past decade have
studies defined the use of prophylactic gamma globulin
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for hepatitis A virus, hepatitis B virus, and nonA, nonB
infection. This discussion will center primarily around
the current role for immunoprophylaxis (vaccines and
gamma globulin) in the management of patients exposed
to hepatitis A and B viruses. Preliminary data and the
recommendations for nonA, nonB infection will be out-
lined.
Preparations
Two commercial preparations are currently available.
The first, immune serum globulin (ISG), is a concentrate
of the antibody component of plasma derived from mul-
tiple donors. This preparation is not currently stand-
ardized for protective hepatitis antibodies (anti-HAV,
anti-HBs). Recent studies have shown that the mean titer
of anti-HAV in random lots of ISG has remained constant
and significant (1 :1000).^°' In contrast to anti-HAV, the
titer of anti-HBs in ISG has changed over the past 15
years. Prior to 1972, titers of anti-HBs were absent or less
than 1 :64. Since then, titers have steadily increased, and
current lots have a mean titer of 1 :500."^ This change in
protective antibody titer may explain in part the ineffec-
tiveness of ISG for serum hepatitis in past studies.
The second preparation, hepatitis B immune globulin
(HBIG), is derived from donors known to have high titers
of anti-HBs. Mean titers for this preparation have been
1 :100,000.''^ Cost and availability ($140 per injection)
have precluded the routine use of HBIG in treating all
types of hepatitis B exposure. HBIG is not recommended
for exposure to hepatitis A or nonA, nonB viruses al-
though significant titers of anti-HAV have been found in
this preparation.
HBIG and ISG are only effective when administered
parenterally. Adverse reactions occur in 1% of patients
when administered intramuscularly or subcutane-
ously."*"'" Intravenous use has been abandoned because
of a high incidence of toxicity (30%) and a significant
risk of anaphylaxis particularly in patients with immuno-
globulin deficiency."** Common side effects include local
pain, fever, and arthralgias which are mild and usually
require no therapy. Recent lots of both preparations have
been free of HBsAg and viral particles and consequently
cannot transmit hepatitis." '̂ Thus, both ISG and HBIG
contain significant titers of protective antibodies, are safe
to administer, and are of potential benefit in hepatitis
prophylaxis.
Hepatitis A
ISG has been consistently proven effective in the
prophylaxis of hepatitis A infection.̂ 3,44 Comparisons
with untreated controls have shown an 80% decrease in
attack rates.""'^" Protection is usually complete but a
minority of patients will develop an attenuated clinical
disease. Two types of prophylaxis have been described.
Postexposure Prophylaxis. Because fecal-oral con-
tact and continuous exposure increase the chances of
contracting hepatitis A infection, certain groups are at
high risk and require prophylaxis. Household contacts
(permanent and temporary) and individuals in in-
stitutionalized settings (prisons, army barracks, chronic
care institutions) require ISG during outbreaks.^' Since
viremia and viral excertion occur early, treatment should
be given to exposed individuals immediately after iden-
tification of an outbreak (<2 weeks). The recommended
treatment is a single dose of ISG (0.02 ml/kg)." ISG
prophylaxis is not required for casual exposure such as
school, work, or hospital contacts except in epidemic
situations since contamination is minimal under these
circumstances. ISG is also not recommended for com-
mon source outbreaks (water or food borne epidemics)
since field studies have shown poor efficacy presumably
because of delays in identifying the outbreak. '̂-^^
Pre-exposure Prophylaxis. Two situations require ISG
before exposure to hepatitis. A. Since hepatitis A virus
is endemic in primates, handlers are at high risk for in-
fection (5% develop clinical hepatitis if untreated).̂ '̂̂ "*
ISG (0.05ml/kg) must be given on a continuous basis
(every four months).^' Pre-exposure prophylaxis is also
warranted for travel to endemic areas, particularly if it is
off the usual tourist routes. Travel for less than three
months requires a single ISG injection (0.02 ml/kg).
More prolonged travel required a higher dose (0.05
ml/kg) given every four to six months.^'
Serotogic Monitoring
Individuals continuously exposed to hepatitis A virus
should have serial monitoring of anti-HAV. Prophylaxis
is unnecessary if endogenous anti-HAV is present. If
anti-HAV titers cannot be readily obtained, immuno-
prophylaxis should not be delayed.
Hepatitis B
The immunoprophylaxis of hepatitis B is controver-
sial.^^ The minimal anti-HBs titer required for effective
prophylaxis is unknown. HBIG is superior to placebo in
preventing clinical hepatitis although its effectiveness in
preventing biochemical disease is less impressive.^*'̂ ^
Postexposure Prophylaxis
S/'ng/e Acute Hepatitis B Surface Antigen Expo-
sure. Mucosal or needle stick contact with
documented HBsAg positive blood requires prophylaxis
unless the recipient is positive for either HBsAg (eg, al-
ready infected) or anti-HBs (eg, has protective an-
tibodies). Thus immediate serologic testing for B virus
markers is imperative both for the donor (patient with
presumed HBs Ag positive blood) and the recipient (in-
dividual exposed to contaminated blood).^' If testing and
results cannot be obtained in seven days, immuno-
prophylaxis should be given. In the exposed individual
without B virus markers, therapy is 0.05-0.07 ml/kg
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treatment.
FIG. 1. Recommended therapy for needle stick, mucus membrane, blood, or sexual exposure to a person suspected of hepatitis B or nonA,
nonB infection.
immediately after exposure and repeated one month la-
ter.*' The repeat dose is required because the incubation
period of hepatitis B can be longer than the half life of
HBIC (28 days).
Sexual contacts. Spouses or recent sexual contacts
(< 1 month) of patients with acute hepatitis B are at
higher risk for contracting infection than other house-
hold or family contacts.**-'^ Although no official rec-
ommendations have been made, there is evidence to
suggest that these individuals should be treated as any
mucosal or needle contact since the risk of infection is
similar.^^ Again, HBsAg and anti-HBs status should de-
termine whether prophylaxis is necessary.*^
Maternal-Infant Prophylaxis. Hepatitis B viral infec-
tion is common in infants whose mothers contracted
hepatitis in the third trimester of pregnancy or shortly
post partum.^'*'"" A chronic carrier state occurs in up to
80% of such infants. Recommendations for this group
are controversial. The risk of increased side effects from
gamma globulin must be weighed against the potential
benefit of preventing chronic liver disease and possibly
hepatoma in these children.*' Prophylaxis of the new-
born infants of chronic HBsAg carriers is even more con-
troversial. HBeAg positivity identifies a subgroup of
mothers more likely to transmit hepatitis B to their in-
fants.̂ ^ Current recommendations are HBIG (0.13 ml/kg)
within seven days of birth, preferably within 48 hours.^'
Repeated dosage at one month has been proposed and
has theoretical merit but is of unproven benefit.^'
Pre-exposure Prophylaxis. There is no compelling
evidence that HBIG or ISG is of any significant benefit in
preventing infection before exposure.*^ Multiple studies
in renal dialysis units, oncology units, and institutions for
the mentally retarded have suggested that meticulous
hygiene may be more important in preventing hepatitis B
virus transmission than immunoprophylaxis.*'-®^
NonA, NonB Hepatitis
No official recommendations regarding immuno-
prophylaxis have been made at this time. Since the epi-
demiology of this infection is similar to hepatitis B,
strong argument can be made for similar prophylaxis
using ISG instead of HBIG.^'' Preliminary studies using
ISG for the prevention of post-transfusion nonA, nonB
hepatitis have been discouraging.^" No data is available
on individuals exposed to single small dose inoculums
(mucosal or needle stick contacts) although it would
seem prudent to treat this type of patient with ISG.
Vaccines
Effective vaccines for hepatitis remain in the de-
velopmental stages. Reasonable progress has only been
made in hepatitis B.'̂  Heat inactivated serum from pa-
tients with hepatitis B has been shown to be noninfec-
tious, antigenic, and partially protective in children and
marmosets exposed to hepatitis B. Preparations of
purified HBsAg have also been shown to induce anti-
HBs and prevent clinical hepatitis under experimental
conditions.'^ Vaccine preparations which contain
smaller polypeptides add to the theoretical safety but
have been less efficacious in preventing clinical or
biochemical disease. Studies designed to optimize pro-
tection and maintain safety are currently in progress.'̂
A recent large community study of HBV vaccine in a
high risk population (homosexuals) gives a convincing
argument for the final eradication of this worldwide
infection.*"
A flow chart for the post-exposure prophylaxis of
hepatitis B and nonA, nonB hepatitis after small in-
oculum contact is presented in Figure 1.
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